Publication
Redefining second-line treatment strategy, sequencing, and real-world implementation in relapsed/refractory multiple myeloma: insights from the 31st Annual Congress of the European Hematology Association.
Ajai Chari, Peter M Voorhees, Raymond Thertulien
Clinical advances in hematology & oncology : H&OSep 1, 2026PMID 42748346Journal ArticleReviewpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
The management of relapsed/refractory (R/R) multiple myeloma (MM) continues to evolve with the introduction of novel therapies and the use of newer therapies in different treatment settings and combinations. Chimeric antigen receptor (CAR) T-cell therapies targeting B-cell maturation antigen (BCMA)…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMultiple Myelomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.